Atezolizumab and Bevacizumab: atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL, Solution concentrate for I.V. infusion 840 mg in 14 mL; bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Tecentriq^® and Avastin^®

Page last updated: 5 March 2021

• Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 1724KB)
• Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 687KB)